Eli Lilly struck a license and research agreement with ABL Bio worth up to $2.6 billion to leverage Grabody‑B, a BBB‑penetrating bispecific platform designed to ferry therapeutics into the central nervous system. The deal includes an upfront payment and hefty milestone and royalty provisions. The pact underscores a fast‑growing industry push to expand CNS delivery solutions; Lilly gains access to a delivery technology intended to deepen its neuroscience pipeline. ABL Bio will receive $40 million up front plus milestone payments and royalties tied to development and commercialization.